An overview of economic evaluations for drugs used in rheumatoid arthritis: Focus on tumour necrosis factor-α antagonists

Drugs

Volumn 65, Issue 4, 2005, Pages 473-496

  Bansback, Nick J ^a,b   Regier, Dean A ^c   Ara, Roberta ^a   Brennan, Alan ^a   Shojania, Kamran ^d   Esdaile, John M ^d   Anis, Aslam H ^d   Marra, Carlo A ^c,d  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ST PAUL S HOSPITAL   (Canada)

^c VANCOUVER COASTAL HEALTH RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANALGESIC AGENT; ANTIMALARIAL AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABSENTEEISM; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; DISEASE MODEL; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMPLOYABILITY; EPIDEMIOLOGICAL DATA; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; INFECTION; INFORMATION PROCESSING; LINEAR REGRESSION ANALYSIS; MEDICAL DECISION MAKING; MEDLINE; METHODOLOGY; MONTE CARLO METHOD; MORTALITY; PATIENT EDUCATION; POPULATION STRUCTURE; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REIMBURSEMENT; RELIABILITY; REVIEW; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TUBERCULOSIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; QUALITY OF LIFE;

EID: 16344370052     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200565040-00004     Document Type: Review

References (109)

1. Kremer JM. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med 2001; 134: 695-706
2. Lovinger SP. Use of biologies for rheumatoid arthritis tempered by concerns over safety, cost. JAMA 2003; 289: 3229-30
3. Michaud K, Messer J, Choi HK, et al. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7527 patients. Arthritis Rheum 2003; 48: 2750-62
4. Jobanputra P, Barton P, Bryan S, et al. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2002; 6 (21): 1-110
5. Choi HK, Seeger JD, Kuntz KM. A cost effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum 2002; 43: 2316-27
6. Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 2002; 113: 400-8
7. Kobelt G, Jonsson L, Young A, et al. The cost-effectiveness of infliximab (Remicade®) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 2003; 42: 326-35
8. Kobelt G, Eberhardt K, Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 2004; 63: 4-10
9. Brennan A, Bansback NJ, Reynolds A, et al. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 2004; 43: 62-72
10. Maetzel A, Tugwell P, Boers M, et al., on behalf of the OMERACT 6 Economics Research group. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a reference case. J Rheumatol 2003; 30: 891-6
11. Maetzel A, Ferraz MB, Bombardier C. A review of cost-effectiveness analyses in rheumatology and related disciplines. Curr Opin Rheumatol 1998; 10: 136-40
12. The Arthritis Society [online]. Available from URL: http://www.arthritis. ca [Accessed 2004 Jan 5]
13. Doran MF, Pond GR, Crowson CS, et al. Trends in the incidence and mortality of rheumatoid arthritis. Arthritis Rheum 2002; 46:625-31
14. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis 2002 update. Arthritis Rheum 2002; 46: 328-46
15. Yelin E, Callahan LF, for the National Arthritis Data Work Group. The economic cost and social psychological impact of musculoskeletal conditions. Arthritis Rheum 1995; 38: 1351-6
16. Pincus T, Callahan LF. The 'side effects' of rheumatoid arthritis: joint destruction, disability, and early mortality. Br J Rheumatol 1993; 32 Suppl. 1: 28-37
17. Gabriel SE, Crowson CS, Kremers HM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003; 48: 54-8
18. Wolfe F, Michaud K, Gefeller O, et al. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48: 1530-42
19. Wong JB, Ramey DR, Singh G. Long-term morbidity, mortality, and economics of rheumatoid arthritis. Arthritis Rheum 2001; 44: 2746-9
20. Choi HK, Hernan MA, Seeger SD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173-7
21. Mutru O, Laasko M, Isomaki H, et al. Cardiovascular mortality in patients with rheumatoid arthritis. Cardiology 1989; 76: 71-7
22. Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based stud. Arthritis Rheum 2002; 46: 2287-93
23. Cibere J, Sibley J, Haga M. Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 1997; 40: 1580-6
24. Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis: a meta-analysis of published clinical trials. Arthritis Rheum 1992; 35: 1117-25
25. Galindo-Rodriguez G, Avina-Zubieta JA, Russell AS, et al. Disappointing longterm results with disease modifying antirheumatic drugs: a practice based study. J Rheumatol 1999; 26: 2337-43
26. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337 (3): 141-7
27. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9
28. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41 (12): 2196-204
29. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48 (1): 35-45
30. Nahar IK, Shojania K, Marra CA, et al. Infliximab treatment of rheumatoid arthritis and Crohn's disease. Ann Pharmacother 2003; 37: 1256-65
31. Humira® (adalimumab) prescribing information [online]. Available from URL: http://www.rxabbott.com/pdf/humira.pdf [Accessed 2004 Feb 12]
32. Bendtsen P, Akerlind I, Hornquist JO. Assessment of quality of life in rheumatoid arthritis: methods and implications. Pharmacoeconomics 1994; 5: 286-98
33. Nichol MB, Harada ASM. Measuring the effects of medication use on health-related quality of life in patients with rheumatoid arthritis: a review. Pharmacoeconomics 1999; 16: 433-48
34. Dominick KL, Ahern FM, Gold CH, et al. Health-related quality of life among older adults with arthritis. Health Qual Life Outcomes 2004; 2 (1): 5
35. Neville C, Whalley D, Mckenna S, et al. Adaptation and validation of the rheumatoid arthritis quality of life scale for use in Canada. J Rheumatol 2001; 28: 1505-10
36. de Jong Z, vand der Heijde D, Mckenna SP, et al. The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument. Br J Rheumatol 1997; 36: 878-83
37. Hurst N, Kind P, Ruta D, et al. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness, and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997; 36: 551-9
38. Marra CA, Woolcott JC, Kopec JA, et al. A comparison of generic, indirect utility measures (the HU12, HU13, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med 2005; 60 (7): 1571-82
39. Callahan LF. The burden of rheumatoid arthritis: facts and figures. J Rheumatol Suppl 1998; 53: 8-12
40. Maetzel A, Strand V, Tugwell P, et al. Cost-effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Rheum 2002; 47: 655-71
41. Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology 2000; 39: 28-33
42. Lubeck DP. A review of the direct costs of rheumatoid arthritis: managed care versus fee-for-service settings. Pharmacoeconomics 2001; 19: 811-8
43. Pugner KM, Scott DI, Holmes JW, et al. The costs of rheumatoid arthritis: an international, long-term view. Semin Arthritis Rheum 2000; 29: 305-20
44. Yelin E, Trupin L, Katz P, et al. Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum 2003; 48: 3046-54
45. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1997
46. Wolfe F, Fries JF. ARAMIS today: moving toward internationally distributed databank systems for follow-up studies. Clin Rheumatol 1987; 6 Suppl. 2: 93-102
47. Young A, Wilkinson P, Talamo J, et al. Socioeconomic deprivation and rheumatoid disease: what lessons for the health service? Ann Rheum Dis 2000; 59: 194-9
48. Young A, Dixey J, Cox N, et al. How does functional disability in early rheumatoid arthritis (RA) affect patients from the Early RA Study. Rheumatology 2000; 38: 603-33
49. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and MTX in severe rheumatoid arthritis: the MTX-Cyclosporine Combination Study Group. N Engl J Med 1995; 333: 137-41
50. O'Dell JR, Haire C, Erikson N, et al. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to MTX. J Rheumatol Suppl 1996; 44: 72-4
51. Crnkic M, Teleman A, Saxne T, et al. Survival on drug as a tool for evaluation of drug tolerability: initial experience in southern Sweden of infliximab, etanercept and leflunomide in rheumatoid arthritis. Rheumatology 2001; 40 Suppl. 1: 82-3
52. Maetzel A, Wong W, Strand V, et al. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology 2000; 39: 975-81
53. Hawley D, Wolfe F. Are the results of controlled clinical trials and observational studies of second line therapy in rheumatoid arthritis valid and generalisable as measures of rheumatoid arthritis outcome. J Rheumatol 1991; 18: 1008-14
54. Lynch N, Robinson E. Cyclosporin use in inflammatory arthritis: a 2-year prospective national audit. Arthritis Rheum 2000; 43 Suppl.: S344
55. Gerards A, Landewe R, Prins A, et al. Combination therapy with cyclosporin A and methotrexate in patients with early aggressive rheumatoid arthritis, a randomised double blind placebo controlled trial. Arthritis Rheum 2000; 43 Suppl.: S382
56. Pincus T, Marcum S, Callahan L. Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices. II: second line drugs and prednisolone. J Rheumatol 1992; 19: 1885-94
57. Eberhardt K, Rydgren L, Petersson H, et al. Early rheumatoid arthritis: onset, course and prognosis over 2 years. Scand J Rheumatol 1990; 17: 253-71
58. Eberhardt K, Fex E. Functional impairment and disability in early rheumatoid arthritis: development over 5 years. J Rhemuatol 1995; 22: 1324-9
59. Eberhardt K, Fex K. Clinical course and remission rate in patients with early rheumatoid arthritis: relationship to outcome after 5 years. Br J Rheumatol 1998; 37: 1324-9
60. Lindqvist E, Saxne T, Geborek P, et al. Ten-year patients: health status, disease process and damage. Ann Rheum Dis 2002; 61: 1055-9
61. Geborek P, Crnkic M, Petersson IF, et al. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. South Swedish Arthritis Treatment Group. Ann Rheum Dis 2002; 61: 793-8
62. Hunink MG, Bull JR, de Vries J, et al. Uncertainty in decision models analyzing cost-effectiveness: the joint distribution of incremental costs and effectiveness evaluated with a nonparametric bootstrap method. Med Decis Making 1998; 18: 337-46
63. New Treatments in arthritis: the use of TNF-α blockers in adults with rheumatoid arthritis. Report of a working party of the British Society for Rheumatology [online]. Available from URL: http://www.msecportal.org/portal/ editorial/public pages/bsr/536883013/1.doc [Accessed 2001 Apr 2]
64. van der Heijde DM, van't Hof M, van Riel PL, et al. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993; 20: 579-81
65. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35
66. Neumann PJ, Goldie SJ, Weinstein MC. Preference-based measures in economic evaluation in health care. Annu Rev Public Health 2000; 21: 587-611
67. Dolan P. The measurement of health-related quality of life for use in resource allocation decisions in health care. In: Culyer AJ, Newhouse JP, editors. Handbook of health economics. London: Elsevier Science, 2000: 1723-60
68. Tengs TO, Wallace A. One thousand health-related quality of life estimates. Med Care 2000; 38: 583-637
69. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals. 2nd ed. Ottawa: The Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1997
70. Kopec JA, Willison KD. A comparative review of four preference-weighted measures of health-related quality of life. J Clin Epidemiol 2003; 56: 317-25
71. Hawthorne G, Richardson J, Day NA. A comparison of the Assessment of Quality of Life (AQoL) with four other generic utility instruments. Ann Med 2001; 33: 358-70
72. Russell AS, Conner-Spady B, Mintz A, et al. The responsiveness of generic health status measures as assessed in patients with rheumatoid arthritis receiving infliximab. J Rheumatol 2003; 30: 941-7
73. Maetzel A, Strand V, Tugwell P, et al. Cost-effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Rheum 2002; 15: 655-61
74. Verhoeven AC, Boers M, van Der Linden S. Responsiveness of the core set, response criteria, and utilities in early rheumatoid arthritis. Ann Rheum Dis 2000; 59: 966-74
75. Tijhuis GJ, Jansen SJ, Stiggelbout AM, et al. Value of the time trade off method for measuring utilities in patients with rheumatoid arthritis. Ann Rheum Dis 2000; 59: 892-7
76. Salaffi F, Stancati A, Carotti M. Responsiveness of health status measures and utility-based methods in patients with rheumatoid arthritis. Clin Rheumatol 2002; 21: 478-87
77. Conner-Spady B, Suarez-Almazor ME. Variation in the estimation of quality adjusted life-years by different preference-based instruments. Med Care 2003; 41: 791-801
78. Luo N, Chew LH, Fong KY, et al. A comparison of the EuroQol-5D and the Health Utilities Index Mark 3 in patients with rheumatic diseases. J Rheumatol 2003; 30: 2268-74
79. Suarez-Almazor ME, Conner-Spady B. Rating of arthritis health states by patients, physicians, and the general public. Implications for cost-utility analyses. J Rheumatol 2001; 28: 648-55
80. Bruce B, Fries J. The Stanford health assessment questionnaire (HAQ): a review of its history, issues, progress, and documentation. J Rheumatol 2003; 30: 167-78
81. Sokka T, Pincus T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum 2003; 48: 313-8
82. Furst DE, Keystone EC, Breedveld FC, et al. Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001). Ann Rheum Dis 2001; 60 Suppl. 3: iii2-5
83. Woodworth TG, Furst DE, Strand V, et al. Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies. J Rheumatol 2001; 28: 1163-9
84. Navarro-Cano G, Del Rincon I, Progosian S, et al. Association of mortality with disease severity in rheumatoid arthritis, independent of comorbidity. Arthritis Rheum 2003 Sep; 48 (9): 2425-33
85. Wolfe F, Kleinheksel SM, Cathey MA, et al. The clinical value of the Stanford health assessment questionnaire functional disability index in patients with rheumatoid arthritis. J Rheumatol 1998; 15: 1480-8
86. Yelin E, Trupin L, Wong B, et al. The impact of functional status and change in functional status on mortality over 18 years among person with rheumatoid arthritis. J Rheumatol 2003; 29: 1851-7
87. Anderson JA, Wells G, Verhoeven AC, et al. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000; 43: 22-9
88. Jobanputra P, Wilson J, Douglas K, et al. A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis. Rheumatology 2004; 43: 206-10
89. Wolfe F, Michaud K, Pincus T. Do rheumatology cost-effectiveness analyses make sense? Rheumatology 2004; 43: 4-6
90. Brennan A, Bansback N. Re: Wolfe, et al. Do rheumatology cost-effectiveness analyses make sense? Rheumatology (Oxford) 2004 May; 43 (5): 677-8
91. Fry RN, Avey SG, Sullivan SD. The academy of managed care pharmacy format for formulary submissions: an evolving standard: a foundation for managed care pharmacy task force report. Value Health 2003; 6: 505-21
92. National Institute for Clinical Excellence. Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis [online]. Available from URL: http://www.nice.org.uk/pdf/RA-PDF.pdf [Accessed 2002 Mar 22]
93. Spector R, Park GD. Regression to the mean: a potential source of error in clinical pharmacological studies. Drug Intell Clin Pharm 1985; 19: 916-9
94. Lesaffre E, Kocmanova D, Lemos PA, et al. A retrospective analysis of the effect of noncompliance on time to first major adverse cardiac event in LIPS. Clin Ther 2003; 25: 2431-47
95. Coyle D, Buxton MJ, O'Brien BJ. Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria. Health Econ 2003; 12: 421-7
96. Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: framework for the marriage of health econometric and cost-effectiveness analysis. Health Econ 2002; 11 (5): 415-30
97. Gold MR, Siegel JE, Russel LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
98. Mushkin S, Collings F, Cost of disease and illness in the United States in the year 2000. Public Health Rep 1978; 93 (5): 493-588
99. Koopmanschap MA, Rutten FF, van Invevel BM, et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14: 171-89
100. Brouwer WB, Koopmanschap MA, Rutten FF. Productivity costs measurement through quality of life? A response to the recommendation of the Washingon Panel. Health Econ 1997; 6: 253-9
101. Weinstein MC, Siegel JE, Garber AM, et al. Productivity costs, time costs and health-related quality of life: a response to the Erasmus group. Health Econ 1997; 6: 505-10
102. Obstfeld M, Rogoff K. Foundations of international macroeconomics. Cambridge (MA): The MIT Press, 1996
103. Stone CE. The lifetime economic costs of rheumatoid arthritis. J Rheumatol 1984; 11: 819-27
104. Meenan RF, Yelin EH, Henke CJ, et al. The costs of rheumatoid arthritis: a patient-oriented study of chronic disease costs. Arthritis Rheum 1978; 21: 827-33
105. Liang MH, Larson M, Thompson M, et al. Costs and outcomes in rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1984; 27: 522-9
106. Jonsson B, Rehnberg C, Borgquist L, et al. Locomotion status and costs in destructive rheumatoid arthritis: a comprehensive study of 82 patients from a population of 13,000. Acta Orthop Scand 1992; 63: 207-12
107. Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 1999; 42: 1209-18
108. Kobelt G, Eberhardt K, Jonsson L, et al. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999; 42: 347-74
109. Lajas C, Abasolo L, Bellajdel B, et al. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum 2003; 49 (1): 64-7